Robert Hans Ingemar Andtbacka

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

Aurélien Marabelle, Robert Hans Ingemar Andtbacka, Kevin J. Harrington et al. · Annals of Oncology · 2018 · 204 citations · Full text

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda et al. · Journal of Clinical Oncology · 2013 · 117 citations

Cancer Management, Immunology, Pathology +19

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

Georgina V. Long, Reinhard Dummer, Antoni Ribas et al. · Journal of Clinical Oncology · 2016 · 110 citations

Immunology, Immune Regulation, Immunoediting +22

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda et al. · Journal of Clinical Oncology · 2013 · 84 citations

Durable Response Rate, Immunology, Immunotherapeutics +21

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

Igor Puzanov, Mohammed Milhem, Robert Hans Ingemar Andtbacka et al. · Journal of Clinical Oncology · 2014 · 82 citations

Ipi Tx, Immunology, Immunoediting +22